These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

329 related articles for article (PubMed ID: 20089697)

  • 21. Abrogation of graft-vs.-leukemia activity after depletion of CD3+ T cells in a murine model of MHC-matched peripheral blood progenitor cell transplantation (PBPCT).
    Uharek L; Glass B; Zeis M; Dreger P; Steinmann J; Löffler H; Schmitz N
    Exp Hematol; 1998 Feb; 26(2):93-9. PubMed ID: 9472798
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Potent in vitro and in vivo activity of an Fc-engineered anti-CD19 monoclonal antibody against lymphoma and leukemia.
    Horton HM; Bernett MJ; Pong E; Peipp M; Karki S; Chu SY; Richards JO; Vostiar I; Joyce PF; Repp R; Desjarlais JR; Zhukovsky EA
    Cancer Res; 2008 Oct; 68(19):8049-57. PubMed ID: 18829563
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Enhanced Cancer Immunotherapy by Chimeric Antigen Receptor-Modified T Cells Engineered to Secrete Checkpoint Inhibitors.
    Li S; Siriwon N; Zhang X; Yang S; Jin T; He F; Kim YJ; Mac J; Lu Z; Wang S; Han X; Wang P
    Clin Cancer Res; 2017 Nov; 23(22):6982-6992. PubMed ID: 28912137
    [No Abstract]   [Full Text] [Related]  

  • 24. In vivo induction of type 1-like regulatory T cells using genetically modified B cells confers long-term IL-10-dependent antigen-specific unresponsiveness.
    Ahangarani RR; Janssens W; VanderElst L; Carlier V; VandenDriessche T; Chuah M; Weynand B; Vanoirbeek JA; Jacquemin M; Saint-Remy JM
    J Immunol; 2009 Dec; 183(12):8232-43. PubMed ID: 20007587
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Adoptive transfer of V beta 2-deleting activity with host cells from mice implanted with C4 preneoplastic hyperplastic alveolar nodules.
    Wei WZ; Wang H; Ficsor-Jacobs R; Pauley R
    Cancer Res; 1992 Oct; 52(19):5183-9. PubMed ID: 1327503
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prevention of Epstein-Barr virus-induced human B-cell lymphoma in severe combined immunodeficient mice treated with CD3xCD19 bispecific antibodies, CD28 monospecific antibodies, and autologous T cells.
    Bohlen H; Manzke O; Titzer S; Lorenzen J; Kube D; Engert A; Abken H; Wolf J; Diehl V; Tesch H
    Cancer Res; 1997 May; 57(9):1704-9. PubMed ID: 9135012
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A tandem CD19/CD20 CAR lentiviral vector drives on-target and off-target antigen modulation in leukemia cell lines.
    Schneider D; Xiong Y; Wu D; Nӧlle V; Schmitz S; Haso W; Kaiser A; Dropulic B; Orentas RJ
    J Immunother Cancer; 2017; 5():42. PubMed ID: 28515942
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Tethered IL15-IL15Rα augments antitumor activity of CD19 CAR-T cells but displays long-term toxicity in an immunocompetent lymphoma mouse model.
    Sánchez-Moreno I; Lasarte-Cia A; Martín-Otal C; Casares N; Navarro F; Gorraiz M; Sarrión P; Hervas-Stubbs S; Jordana L; Rodriguez-Madoz JR; San Miguel J; Prosper F; Lasarte JJ; Lozano T
    J Immunother Cancer; 2024 Jul; 12(7):. PubMed ID: 38955421
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Characterization of in vitro migratory properties of anti-CD19 chimeric receptor-redirected CIK cells for their potential use in B-ALL immunotherapy.
    Marin V; Dander E; Biagi E; Introna M; Fazio G; Biondi A; D'Amico G
    Exp Hematol; 2006 Sep; 34(9):1219-29. PubMed ID: 16939815
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Different phenotypic variants of the mouse B cell tumor A20/2J are selected by antigen- and mitogen-triggered cytotoxicity of L3T4-positive, I-A-restricted T cell clones.
    Jones B; Tite JP; Janeway CA
    J Immunol; 1986 Jan; 136(1):348-56. PubMed ID: 2415625
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A functional role for CD28 costimulation in tumor recognition by single-chain receptor-modified T cells.
    Moeller M; Haynes NM; Trapani JA; Teng MW; Jackson JT; Tanner JE; Cerutti L; Jane SM; Kershaw MH; Smyth MJ; Darcy PK
    Cancer Gene Ther; 2004 May; 11(5):371-9. PubMed ID: 15060573
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Adoptive cellular immunotherapy with CD19-specific T cells.
    Rössig C; Pscherer S; Landmeier S; Altvater B; Jürgens H; Vormoor J
    Klin Padiatr; 2005; 217(6):351-6. PubMed ID: 16307422
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Adoptive transfer of in vitro-targeted, activated T lymphocytes results in total tumor regression.
    Altenschmidt U; Klundt E; Groner B
    J Immunol; 1997 Dec; 159(11):5509-15. PubMed ID: 9548491
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Characterization of the effector mechanism of help for antigen-presenting and bystander resting B cell growth mediated by Ia-restricted Th2 helper T cell lines.
    Whalen BJ; Tony HP; Parker DC
    J Immunol; 1988 Oct; 141(7):2230-9. PubMed ID: 2971722
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Genetically targeted T cells eradicate systemic acute lymphoblastic leukemia xenografts.
    Brentjens RJ; Santos E; Nikhamin Y; Yeh R; Matsushita M; La Perle K; Quintás-Cardama A; Larson SM; Sadelain M
    Clin Cancer Res; 2007 Sep; 13(18 Pt 1):5426-35. PubMed ID: 17855649
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Bryostatin 1/ionomycin (B/I) ex vivo stimulation preferentially activates L-selectinlow tumor-sensitized lymphocytes.
    Chin CS; Miller CH; Graham L; Parviz M; Zacur S; Patel B; Duong A; Bear HD
    Int Immunol; 2004 Sep; 16(9):1283-94. PubMed ID: 15262898
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Retrovirally transduced bone marrow-derived dendritic cells require CD4+ T cell help to elicit protective and therapeutic antitumor immunity.
    De Veerman M; Heirman C; Van Meirvenne S; Devos S; Corthals J; Moser M; Thielemans K
    J Immunol; 1999 Jan; 162(1):144-51. PubMed ID: 9886380
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Development and application of CD19-specific T cells for adoptive immunotherapy of B cell malignancies.
    Cooper LJ; Al-Kadhimi Z; DiGiusto D; Kalos M; Colcher D; Raubitschek A; Forman SJ; Jensen MC
    Blood Cells Mol Dis; 2004; 33(1):83-9. PubMed ID: 15223016
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Synergistic enhancement of antitumor immunity with adoptively transferred tumor-specific CD4+ and CD8+ T cells and intratumoral lymphotactin transgene expression.
    Huang H; Li F; Gordon JR; Xiang J
    Cancer Res; 2002 Apr; 62(7):2043-51. PubMed ID: 11929823
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cyclophosphamide enhances the antitumor efficacy of adoptively transferred immune cells through the induction of cytokine expression, B-cell and T-cell homeostatic proliferation, and specific tumor infiltration.
    Bracci L; Moschella F; Sestili P; La Sorsa V; Valentini M; Canini I; Baccarini S; Maccari S; Ramoni C; Belardelli F; Proietti E
    Clin Cancer Res; 2007 Jan; 13(2 Pt 1):644-53. PubMed ID: 17255288
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.